153 related articles for article (PubMed ID: 31464608)
21. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Alegre A; Oriol-Rocafiguera A; Garcia-Larana J; Mateos MV; Sureda A; Martinez-Chamorro C; Cibeira MT; Aguado B; Knight R; Rosettani B
Leuk Lymphoma; 2012 Sep; 53(9):1714-21. PubMed ID: 22292853
[TBL] [Abstract][Full Text] [Related]
22. A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.
Ghesquières H; Rossi C; Cherblanc F; Le Guyader-Peyrou S; Bijou F; Sujobert P; Fabbro-Peray P; Bernier A; Belot A; Chartier L; Fornecker LM; Baldi I; Bouabdallah K; Laurent C; Oberic L; Morineau N; Le Gouill S; Morschhauser F; Haioun C; Damaj G; Guidez S; Labouré G; Fitoussi O; Lebras L; Gressin R; Salles G; Ysebaert L; Monnereau A
BMC Public Health; 2021 Mar; 21(1):432. PubMed ID: 33653294
[TBL] [Abstract][Full Text] [Related]
23. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
24. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.
Yang HH; Vescio R; Schenkein D; Berenson JR
Clin Lymphoma; 2003 Sep; 4(2):119-22. PubMed ID: 14556685
[No Abstract] [Full Text] [Related]
25. Pooled analysis of pomalidomide for treating patients with multiple myeloma.
Sun JJ; Zhang C; Zhou J; Yang HL
Asian Pac J Cancer Prev; 2015; 16(8):3163-6. PubMed ID: 25921115
[TBL] [Abstract][Full Text] [Related]
26. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
27. Multiple myeloma.
Harousseau JL; Shaughnessy J; Richardson P
Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
[TBL] [Abstract][Full Text] [Related]
28. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
29. [Pathology and treatment of multiple myeloma understood from the tumor cell-of-origin perspective].
Tanaka H
Rinsho Ketsueki; 2020; 61(9):1317-1324. PubMed ID: 33162531
[TBL] [Abstract][Full Text] [Related]
30. Novel combination approaches for myeloma.
Lonial S; Nooka AK
Hematology Am Soc Hematol Educ Program; 2015; 2015():286-93. PubMed ID: 26637735
[No Abstract] [Full Text] [Related]
31. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.
Song KW; Dimopoulos MA; Weisel KC; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Monzini MS; Zaki M; Jacques C; San Miguel J
Haematologica; 2015 Feb; 100(2):e63-7. PubMed ID: 25425684
[No Abstract] [Full Text] [Related]
32. Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.
Stöhr E; Schmeel FC; Schmeel LC; Hänel M; Schmidt-Wolf IG;
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2205-12. PubMed ID: 26156122
[TBL] [Abstract][Full Text] [Related]
33. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Vose JM; Panwalkar A; Belanger R; Coiffier B; Baccarani M; Gregory SA; Facon T; Fanin R; Caballero D; Ben-Yehuda D; Giles F
Leuk Lymphoma; 2007 Jan; 48(1):39-45. PubMed ID: 17325846
[TBL] [Abstract][Full Text] [Related]
34. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
35. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
36. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
38. A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
Benson DM; Cohen AD; Jagannath S; Munshi NC; Spitzer G; Hofmeister CC; Efebera YA; Andre P; Zerbib R; Caligiuri MA
Clin Cancer Res; 2015 Sep; 21(18):4055-61. PubMed ID: 25999435
[TBL] [Abstract][Full Text] [Related]
39. Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; DeMarco D; Zhang J; Mei J; Hou J
BMC Cancer; 2016 Jan; 16():46. PubMed ID: 26821931
[TBL] [Abstract][Full Text] [Related]
40. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?
Sonneveld P; De Wit E; Moreau P
Crit Rev Oncol Hematol; 2017 Apr; 112():153-170. PubMed ID: 28325256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]